Inhibikase Therapeutics (IKT) Net Margin (2020 - 2023)
Inhibikase Therapeutics (IKT) reported Net Margin of -417794000.00% for Q4 2023, down 417787268.33 percentage points from -6731.67% a year earlier and down 417788224.89 percentage points from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Net Margin (2020 - 2023) Analysis & Trends
For FY2023, Inhibikase Therapeutics posted Net Margin of -7304.73%, up 7321.13 percentage points from FY2022.
- Net Margin has a three-year change of -6896.99 percentage points (FY2020 to FY2023).
- By year, Net Margin came in at -14625.85% in FY2022 (-14148.98 pp), -476.88% in FY2021 (-69.14 pp) and -407.73% in FY2020.
- The Q4 2023 figure ranks as the lowest quarterly Net Margin in data going back to Q1 2020.
- Year over year, Net Margin gained in four of the last eight quarters, with an average year-over-year change of -52193824.25 percentage points.
- The high point for year-over-year Net Margin in five years was Q4 2022 (a gain of 252610.87 percentage points); the low point was Q4 2023 (a drop of 417787268.33 percentage points).
- Per Business Quant data, the three quarters before Q4 2023 came in at -5775.11% (Q3 2023), -4963.46% (Q2 2023) and -6940.03% (Q1 2023).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 21.86% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 21.27% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | -8.04% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 22.61% |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 18.81% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 23.62% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -134.51% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | -1.65% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 32.99% |
| 10 | Inhibikase Therapeutics | 357.87 Mn | -227.60 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -417,794,000.00% |
| Sep 30, 2023 | -5,775.11% |
| Jun 30, 2023 | -4,963.46% |
| Mar 31, 2023 | -6,940.03% |
| Dec 31, 2022 | -6,731.67% |
| Sep 30, 2022 | -61,645.36% |
| Jun 30, 2022 | -70,817.14% |
| Mar 31, 2022 | -10,081.47% |
| Dec 31, 2021 | -259,342.54% |
| Sep 30, 2021 | -1,361.26% |
| Jun 30, 2021 | -193.40% |
| Mar 31, 2021 | -187.40% |
| Dec 31, 2020 | -708.85% |
| Sep 30, 2020 | -1,779.72% |
| Jun 30, 2020 | -192.12% |
| Mar 31, 2020 | -202.17% |
API Access
Inhibikase Therapeutics Net Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-margin&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-margin", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-margin&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();